Spero Therapeutics (SPRO) Net Income (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed Net Income for 10 consecutive years, with -$6.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Net Income rose 61.3% year-over-year to -$6.8 million, compared with a TTM value of -$43.1 million through Sep 2025, down 1552.76%, and an annual FY2024 reading of -$68.6 million, down 400.73% over the prior year.
- Net Income was -$6.8 million for Q3 2025 at Spero Therapeutics, down from -$1.7 million in the prior quarter.
- Across five years, Net Income topped out at $51.2 million in Q4 2023 and bottomed at -$30.1 million in Q1 2022.
- Average Net Income over 5 years is -$10.6 million, with a median of -$13.9 million recorded in 2025.
- The sharpest move saw Net Income soared 181.17% in 2022, then tumbled 684.97% in 2024.
- Year by year, Net Income stood at -$27.4 million in 2021, then skyrocketed by 181.17% to $22.3 million in 2022, then soared by 129.93% to $51.2 million in 2023, then tumbled by 140.43% to -$20.7 million in 2024, then surged by 66.9% to -$6.8 million in 2025.
- Business Quant data shows Net Income for SPRO at -$6.8 million in Q3 2025, -$1.7 million in Q2 2025, and -$13.9 million in Q1 2025.